CONTEXT THERAPEUTICS INC (CNTX)

US21077P1084 - Common Stock

1.02  -0.07 (-6.42%)

After market: 1.06 +0.04 (+3.92%)

News Image
2 months ago - Context Therapeutics Inc.

Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results

Expands pipeline of T cell engaging bispecific antibodies through acquisitions of CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x...

News Image
2 months ago - Context Therapeutics Inc.

Context Therapeutics to Participate in Upcoming Investor Conferences in November

PHILADELPHIA, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing...

News Image
2 months ago - Context Therapeutics Inc.

Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

PHILADELPHIA, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing...

News Image
3 months ago - Context Therapeutics Inc.

BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody

Context to obtain exclusive development and commercialization rights to BA3362 BioAtla to receive $15.0 million in upfront and near-term milestones, and...

News Image
4 months ago - Context Therapeutics Inc.

Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors

The appointments of Dr. Karen Smith and Dr. Luke Walker to the Board bring extensive operational and clinical development experience to support corporate and pipeline strategy

News Image
4 months ago - Context Therapeutics Inc.

Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors

The appointments of Dr. Karen Smith and Dr. ...

News Image
5 months ago - Context Therapeutics Inc.

Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results

Announced acquisition of CT-95, a mesothelin x CD3 bispecific antibody Claudio Dansky Ullmann, M.D. named Chief Medical Officer Cash and cash equivalents...

News Image
5 months ago - Context Therapeutics Inc.

Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations

Company announces appointments of Dr. Claudio Dansky Ullmann as CMO and Ms. Karen Andreas as VP, Clinical Operations

News Image
6 months ago - Context Therapeutics Inc.

Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95

CT-95 is a potentially first-in-class mesothelin x CD3 bispecific antibody Acquisition expands Context pipeline with second clinical-stage T cell engager...

News Image
7 months ago - InvestorPlace

Hypergrowth Hits: 3 Stocks Clocking Triple-Digit Gains with No End in Sight

If you believe in chasing the winners higher, here are three hypergrowth stocks that may provide Nvidia-like gains.

News Image
7 months ago - InvestorPlace

The 100%+ Club: Piper Sandler’s 3 Top Picks for Triple-Digit Gains

Biotechs can see triple-digit returns or dramatic losses but these Piper Sandler stocks have the potential to achieve them.

News Image
8 months ago - InvestorPlace

CNTX Stock Earnings: Context Therapeutics Beats EPS for Q1 2024

CNTX stock results show that Context Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.

News Image
8 months ago - BusinessInsider

CNTX Stock Earnings: Context Therapeutics Beats EPS for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Context Therapeutics (NASDAQ:CNTX) just reported results for the first quarter ...

News Image
8 months ago - Context Therapeutics Inc.

Context Therapeutics Reports First Quarter 2024 Operating and Financial Results

Announced FDA clearance of IND application for a Phase 1 clinical trial of CTIM-76 Completed $100 million financing; expected to extend funding into 2028 ...

News Image
8 months ago - Context Therapeutics Inc.

Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76

CTIM-76 Phase 1 clinical trial to focus on CLDN6-positive gynecologic and testicular cancers Company expects to enroll first patient in mid-2024 ...

News Image
9 months ago - Context Therapeutics Inc.

Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers

Important Regulatory Milestone Supports Next Phase of CTIM-76 Development

News Image
9 months ago - Context Therapeutics Inc.

Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers

Important Regulatory Milestone Supports Next Phase of CTIM-76 Development...

News Image
9 months ago - InvestorPlace

CNTX Stock Earnings: Context Therapeutics Misses EPS for Q4 2023

CNTX stock results show that Context Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.

News Image
9 months ago - BusinessInsider

CNTX Stock Earnings: Context Therapeutics Misses EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Context Therapeutics (NASDAQ:CNTX) just reported results for the fourth quarter...

News Image
9 months ago - Context Therapeutics Inc.

Context Therapeutics Reports Full Year 2023 Operating and Financial Results

CTIM-76 IND filing on track for late March 2024 Cash and cash equivalents of $14.4 million as of December 31, 2023 Company expects its cash and cash...